QVAR® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for systemic corticosteroids.
Important Safety Information
- QVAR is not a bronchodilator and is not indicated for relief of acute bronchospasm
- Common side effects associated with the use of QVAR and placebo in clinical trials include, but are not limited to, headache (12% and 9%,
respectively) and pharyngitis (8% and 4%, respectively)
CAUTION: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information)
- A reduction in growth velocity in growing children and teenagers may occur as a result of inadequate control of chronic diseases such as asthma
or from use of corticosteroids for treatment
References:
- Martin RJ. Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol. 2002;109(2):S447-S460.
- Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol. 1992;72:1016-1023.
080719